Kunle Odunsi
#109,499
Most Influential Person Now
Kunle Odunsi's AcademicInfluence.com Rankings
Kunle Odunsiphilosophy Degrees
Philosophy
#8186
World Rank
#11518
Historical Rank
Logic
#5216
World Rank
#6598
Historical Rank
Kunle Odunsibiology Degrees
Biology
#9137
World Rank
#12305
Historical Rank
Immunology
#542
World Rank
#559
Historical Rank
Download Badge
Philosophy Biology
Why Is Kunle Odunsi Influential?
(Suggest an Edit or Addition)According to Wikipedia, Adekunle O. Odunsi is an American gynecologic oncologist. In 2020, Odunsi was named the director of the University of Chicago Comprehensive Cancer Center. Early life and education Growing up in Nigeria, Odunsi attended the University of Ife for his Bachelor of Science degree and medical degree. Following this, he completed his PhD in immunogenetics at the Weatherall Institute of Molecular Medicine.
Kunle Odunsi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. (2012) (6726)
- Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. (2005) (2181)
- Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk (2015) (838)
- Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer (2010) (686)
- The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. (2010) (646)
- Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
- Gene expression markers of Tumor Infiltrating Leukocytes (2016) (482)
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2011) (447)
- Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. (2015) (390)
- PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. (2011) (386)
- A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. (2008) (357)
- GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer (2013) (350)
- Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. (2013) (339)
- Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. (2015) (333)
- Detection of epithelial ovarian cancer using 1H‐NMR‐based metabonomics (2005) (328)
- Non-redundant Requirement for CXCR3 Signaling during Tumoricidal T Cell Trafficking across Tumor Vascular Checkpoints (2015) (327)
- Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism (2014) (310)
- Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer (2008) (286)
- Common variants at 19p13 are associated with susceptibility to ovarian cancer (2010) (262)
- Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. (2015) (262)
- Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer (2007) (255)
- NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. (2003) (243)
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer (2016) (208)
- LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model (2015) (203)
- Identification of six new susceptibility loci for invasive epithelial ovarian cancer (2014) (176)
- Seromic profiling of ovarian and pancreatic cancer (2010) (174)
- PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients (2012) (173)
- Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer (2013) (167)
- A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. (2011) (159)
- Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer (2014) (157)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry (2017) (149)
- Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. (2016) (146)
- The evolution and population genetics of the ALDH2 locus: random genetic drift, selection, and low levels of recombination (2004) (144)
- Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. (2009) (140)
- T cell assays and MIATA: the essential minimum for maximum impact. (2012) (134)
- CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells (2014) (123)
- CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. (2012) (123)
- Humanized Mouse Model of Ovarian Cancer Recapitulates Patient Solid Tumor Progression, Ascites Formation, and Metastasis (2011) (113)
- Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 (2013) (110)
- Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity (2011) (106)
- DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. (2007) (104)
- Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling (2013) (103)
- PGE2-Driven Induction and Maintenance of Cancer-Associated Myeloid-Derived Suppressor Cells (2012) (101)
- Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. (2010) (98)
- Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells (2017) (97)
- Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies (2013) (95)
- Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers (2012) (92)
- Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. (2002) (90)
- Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer (2008) (89)
- Immunotherapy in ovarian cancer. (2017) (89)
- Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. (2006) (89)
- Immunotherapy in ovarian cancer (2017) (88)
- Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. (2008) (88)
- Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery (2018) (86)
- Pelvic exenterations for gynecological malignancies: twenty‐year experience at Roswell Park Cancer Institute (2005) (83)
- Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. (2019) (83)
- Genome-wide significant risk associations for mucinous ovarian carcinoma (2015) (81)
- Regulating Mammalian Target of Rapamycin To Tune Vaccination-Induced CD8+ T Cell Responses for Tumor Immunity (2012) (80)
- Susceptibility to human papillomavirus‐associated cervical intra‐epithelial neoplasia is determined by specific HLA DR‐DQ alleles (1996) (80)
- NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer (2012) (79)
- Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA ) (2011) (78)
- Hurdles to Lymphocyte Trafficking in the Tumor Microenvironment: Implications for Effective Immunotherapy (2006) (76)
- Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients (2015) (75)
- Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. (2011) (74)
- Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade (2015) (74)
- Coordinated Cancer Germline Antigen Promoter and Global DNA Hypomethylation in Ovarian Cancer: Association with the BORIS/CTCF Expression Ratio and Advanced Stage (2011) (74)
- Diagnostic utility of FLI‐1 monoclonal antibody and dual‐colour, break‐apart probe fluorescence in situ (FISH) analysis in Ewing's sarcoma/primitive neuroectodermal tumour (EWS/PNET). A comparative study with CD99 and FLI‐1 polyclonal antibodies (2006) (74)
- First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients (2012) (73)
- Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody (2006) (73)
- Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses (2015) (73)
- Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies. (2010) (71)
- Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium (2009) (70)
- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
- Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond (2010) (68)
- Association Between HLA DQBl * 03 and Cervical Intra-epithelial Neoplasia (1995) (68)
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (2016) (67)
- Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (2006) (67)
- Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study (2014) (65)
- Interleukin 2-mediated Conversion of Ovarian Cancer-associated CD4+ Regulatory T Cells Into Proinflammatory Interleukin 17-producing Helper T Cells (2009) (64)
- Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer (2014) (63)
- Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. (2020) (63)
- Sialic Acid–Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments (2018) (63)
- NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome (2017) (62)
- Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients. (2013) (62)
- Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients (2011) (61)
- Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. (2016) (60)
- Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination1 (2006) (60)
- Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2012) (60)
- Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation (2012) (59)
- A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI) (2013) (58)
- Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer (2009) (58)
- Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (2016) (58)
- IL-12-Programmed Long-Term CD8+ T Cell Responses Require STAT41 (2006) (57)
- Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. (2008) (57)
- Immunotherapy in Ovarian Cancer: Are We There Yet? (2019) (57)
- Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression. (2017) (57)
- Deep depletion of abundant serum proteins reveals low‐abundant proteins as potential biomarkers for human ovarian cancer (2009) (57)
- Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression (2015) (56)
- PRAME expression and promoter hypomethylation in epithelial ovarian cancer (2016) (55)
- Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. (2005) (54)
- Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature (2016) (54)
- Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses (2018) (53)
- A Small-Molecule Inhibitor Targeting the Mitotic Spindle Checkpoint Impairs the Growth of Uterine Leiomyosarcoma (2012) (52)
- Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients (2019) (51)
- Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer (2018) (51)
- Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer (2019) (51)
- Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer (2015) (50)
- Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer (2015) (49)
- DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer (2015) (49)
- Immunologic approaches to ovarian cancer treatment. (2007) (48)
- Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. (2009) (48)
- Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. (2017) (48)
- T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors (2021) (48)
- IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. (2010) (48)
- Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages (2007) (47)
- A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (2017) (47)
- NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. (2017) (47)
- The CD47 "don't eat me signal" is highly expressed in human ovarian cancer. (2016) (46)
- Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens (2017) (46)
- Young patients with endometrial carcinoma selected for conservative treatment: a need for vigilance for synchronous ovarian carcinomas, case report and literature review. (2007) (45)
- Novel genetic variants in miR-191 gene and familial ovarian cancer (2010) (45)
- LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. (2014) (45)
- IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. (2009) (45)
- DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11 (2013) (44)
- Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4+ T Cells (2013) (44)
- Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression (2011) (44)
- Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer (2002) (42)
- Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro (2012) (42)
- Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. (2014) (42)
- The impact of pre-therapy extraperitoneal surgical staging on the evaluation and treatment of patients with locally advanced cervical cancer. (2001) (42)
- Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment (2016) (41)
- A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases (2019) (41)
- Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium (2016) (41)
- Pathogenesis of mediastinal paravertebral müllerian cysts of Hattori: developmental endosalpingiosis-müllerianosis. (2010) (40)
- Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer (2015) (40)
- OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. (2006) (39)
- PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. (2016) (39)
- A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. (2005) (37)
- Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies (2019) (37)
- Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk (2015) (36)
- Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing (2016) (36)
- Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer (2019) (35)
- Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells (2006) (35)
- Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells. (2013) (35)
- Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types (2017) (34)
- DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer (2016) (34)
- Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability (2020) (33)
- Heat Shock Protein 90-Mediated Peptide-Selective Presentation of Cytosolic Tumor Antigen for Direct Recognition of Tumors by CD4+ T Cells (2012) (33)
- Evaluation of the National Surgical Quality Improvement Program Universal Surgical Risk Calculator for a Gynecologic Oncology Service (2014) (33)
- Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. (2004) (33)
- Methylation of death‐associated protein kinase in ovarian carcinomas (2006) (31)
- Well-differentiated mucinous carcinoma of the ovary and a coexisting Brenner tumor both exhibit amplification of 12q14-21 by comparative genomic hybridization. (1999) (31)
- Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T Cell Exhaustion. (2021) (30)
- Prostate derived Ets transcription factor shows better tumor-association than other cancer-associated molecules. (2004) (30)
- Clinical and Pathological Predictive Factors in Women with Adult-type Granulosa Cell Tumor of the Ovary (2007) (29)
- A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. (2014) (29)
- Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes. (2009) (29)
- SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. (2004) (29)
- CX3CR1-CD8+ T cells are critical in antitumor efficacy, but functionally suppressed in the tumor microenvironment. (2020) (29)
- Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference (2019) (29)
- BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. (2010) (28)
- Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. (2017) (28)
- High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies (2010) (27)
- Primary primitive neuroectodermal tumor of the uterus: a report of two cases and review of the literature. (2004) (27)
- negatively regulated by LAG-3 and PD-1 in human ovarian cancer (2010) (27)
- Prostate‐derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients (2008) (27)
- Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma. (2012) (27)
- Somatic D-loop mitochondrial DNA mutations are frequent in uterine serous carcinoma. (2004) (27)
- IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation (2021) (26)
- Frequent MAGE Mutations in Human Melanoma (2010) (26)
- Efficacy of adjuvant CYVADIC chemotherapy in early‐stage uterine sarcomas: results of long‐term follow‐up (2004) (26)
- Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. (2010) (26)
- Inactivating Mutations in GT198 in Familial and Early-Onset Breast and Ovarian Cancers. (2013) (26)
- A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncolog (2017) (26)
- History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium (2017) (26)
- Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC) (2015) (26)
- PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. (2012) (26)
- Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1 (2008) (25)
- BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. (2013) (25)
- Prostate-Specific Membrane Antigen Expression Is a Potential Prognostic Marker in Endometrial Adenocarcinoma (2008) (25)
- Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer. (2015) (25)
- Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA (2013) (24)
- Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. (2004) (24)
- Active Immunotherapy of Cancer (2015) (24)
- Breastfeeding factors and risk of epithelial ovarian cancer. (2019) (24)
- Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils (2020) (24)
- A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols (2011) (24)
- Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy (2016) (24)
- CD4+ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg (2013) (24)
- Evaluation of chemical tests for fetal bleeding from vasa previa (1996) (23)
- Identification of differentially expressed genes in clinically distinct groups of serous ovarian carcinomas using cDNA microarray. (2004) (23)
- ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma (2019) (22)
- Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer (2019) (22)
- Expression of Poly (Adenosine Diphosphate-Ribose) Polymerase and p53 in Epithelial Ovarian Cancer and Their Role in Prognosis and Disease Outcome (2011) (22)
- Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas. (2008) (22)
- Inherited Variants in Regulatory T Cell Genes and Outcome of Ovarian Cancer (2013) (21)
- REVIEW ARTICLE: Harnessing the Immune System for Ovarian Cancer Therapy (2007) (21)
- First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1 (2019) (21)
- TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. (2015) (21)
- Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk (2015) (21)
- Characterization of a Putative Ovarian Oncogene, Elongation Factor 1α, Isolated by Panning a Synthetic Phage Display Single-Chain Variable Fragment Library with Cultured Human Ovarian Cancer Cells (2007) (21)
- Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model. (2013) (21)
- Metabolomic prediction of endometrial cancer (2017) (21)
- Epigenetic activation of POTE genes in ovarian cancer (2019) (20)
- Immune Therapy Opportunities in Ovarian Cancer. (2020) (20)
- Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers (2015) (20)
- Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome (2014) (20)
- Expression of the POTE gene family in human ovarian cancer (2018) (20)
- Pelvic exenterations for gynecological malignancies: twenty-year experience at Roswell Park Cancer Institute (2004) (19)
- Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. (2017) (19)
- Aspirin and Acetaminophen Use and the Risk of Cervical Cancer (2015) (19)
- Celyad's novel CAR T-cell therapy for solid malignancies. (2018) (19)
- Myeloid-Derived Suppressor Cells Modulate Immune Responses Independently of NADPH Oxidase in the Ovarian Tumor Microenvironment in Mice (2013) (19)
- Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer. (2012) (18)
- Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer (2016) (18)
- History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report (2017) (18)
- Primary fallopian tube carcinoma: a retrospective clinicopathologic study. (2006) (18)
- Predictors of Immunosuppressive Regulatory T Lymphocytes in Healthy Women (2012) (18)
- No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
- Tumor infiltrating lymphocytes: indicators of tumor-related immune responses. (2007) (18)
- Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer (2021) (17)
- Primary vaginal adenocarcinoma arising in vaginal adenosis after CO2 laser vaporization and 5-fluorouracil therapy. (2010) (17)
- Oxaliplatin Is a Safe Alternative Option for Patients With Recurrent Gynecologic Cancers After Hypersensitivity Reaction to Carboplatin (2015) (17)
- Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. (2015) (17)
- Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene (2017) (16)
- Gene expression and prognostic significance in ovarian cancer. (2004) (16)
- Evaluation of the possible protective role of adeno-associated virus type 2 infection in HPV-associated premalignant disease of the cervix. (2000) (16)
- A phase II trial of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (2019) (16)
- Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease (2016) (16)
- Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers (2012) (16)
- The roles of the human major histocompatibility complex and human papillomavirus infection in cervical intraepithelial neoplasia and cervical cancer. (1997) (16)
- Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients (2019) (15)
- Monoclonal antibody MX 35 detects the membrane transporter NaPi 2 b ( SLC 34 A 2 ) in human carcinomas (2005) (15)
- Developmentally Restricted Differentiation Antigens Are Targets for Immunotherapy in Epithelial Ovarian Carcinoma (2013) (15)
- Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing (2019) (15)
- Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer (2019) (15)
- Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses (2022) (15)
- Tumor associated antigen recognition by autologous serum in patients with breast cancer. (2005) (15)
- Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma. (2010) (14)
- Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17 q 21 . 31 (2013) (14)
- Standard operating procedure for metabonomics studies of blood serum and plasma samples using a 1H‐NMR micro‐flow probe (2009) (14)
- Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions (2019) (14)
- Reporting of quality measures in gynecologic oncology programs at Prospective Payment System (PPS)-Exempt Cancer Hospitals: an early glimpse into a challenging initiative. (2013) (14)
- Split T Cell Tolerance against a Self/Tumor Antigen: Spontaneous CD4+ but Not CD8+ T Cell Responses against p53 in Cancer Patients and Healthy Donors (2011) (14)
- A paradigm for finding genes for a complex human trait: polycystic ovary syndrome and follistatin. (1999) (14)
- Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments (2021) (13)
- Epithelioid sarcoma of the vulva in a 17-year-old pregnant woman. (2009) (13)
- Cancer Immunotherapy Principles and Practice (2018) (13)
- RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization (2020) (13)
- Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers. (2004) (13)
- Tumor antigens and markers for breast and ovarian cancers. (2002) (13)
- Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium (2019) (13)
- Antigen‐induced Erk1/2 activation regulates Ets‐1‐mediated sensitization of CD8+ T cells for IL‐12 responses (2010) (13)
- Motif analysis of HLA class II molecules that determine the HPV associated risk of cervical carcinogenesis. (2001) (13)
- Cyclooxygenase 2 Expression in Serous Tumors of the Ovary (2005) (12)
- WHSC1/NSD2 regulates immune infiltration in prostate cancer (2021) (12)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) (2018) (12)
- Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006. (2009) (12)
- Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study (2018) (12)
- Array-Comparative Genomic Hybridization Analysis of Primary Endometrial and Ovarian High-grade Neuroendocrine Carcinoma Associated With Adenocarcinoma: Mystery Resolved? (2008) (12)
- Serous adenocarcinoma of the uterus presenting as paraneoplastic cerebellar degeneration. (1999) (12)
- 14-3-3sigma expression and prognostic value in patients with epithelial ovarian carcinoma: a high throughput tissue microarray analysis. (2009) (12)
- Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer. (2006) (12)
- Photodynamic therapy effectively palliates gynecologic malignancies. (2012) (12)
- Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. (2017) (12)
- Oncologist uptake of comprehensive genomic profile guided targeted therapy (2019) (12)
- Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study (2018) (12)
- CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer (2020) (11)
- Tumor-associated macrophages: co-conspirators and orchestrators of immune suppression in endometrial adenocarcinoma. (2014) (11)
- In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models (2021) (11)
- Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. (2014) (11)
- Usual Adult Body Mass Index Is Not Predictive of Ovarian Cancer Survival (2007) (11)
- A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells (2019) (11)
- Evaluation of β1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer☆ (2002) (11)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (11)
- Endometriosis of the retrocervical septum is proposed to replace the anatomically incorrect term endometriosis of the rectovaginal septum. (2014) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer (2020) (10)
- Nature of tumour rejection antigens in ovarian cancer (2018) (10)
- Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration (2016) (10)
- Impact of Physical Inactivity on Risk of Developing Cancer of the Uterine Cervix: A Case-Control Study (2016) (10)
- Whole‐exome sequencing of ovarian cancer families uncovers putative predisposition genes (2019) (10)
- Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy (2018) (10)
- Sublethal Radiation Affects Antigen Processing and Presentation Genes to Enhance Immunogenicity of Cancer Cells (2020) (10)
- Ovarian primary primitive neurectodermal tumor coexisting with endometrioid adenocarcinoma: a case report. (2006) (10)
- Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens (2021) (9)
- Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy (2016) (9)
- Use of Common Analgesics Is Not Associated with Ovarian Cancer Survival (2015) (9)
- A case of fatal pulmonary thromboembolism associated with the use of intravenous estrogen therapy. (1999) (9)
- Cancer diagnostics using 1H-NMR-based metabonomics. (2007) (9)
- RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization (2021) (9)
- Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility (2018) (9)
- A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation (2012) (9)
- Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. (2018) (9)
- Complex Segregation Analysis of Pedigrees from the Gilda Radner Familial Ovarian Cancer Registry Reveals Evidence for Mendelian Dominant Inheritance (2009) (9)
- Reassessment of pelvic lymph node debulking in advanced cervical cancer. (2004) (9)
- History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium (2017) (8)
- Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium. (2010) (8)
- Targeted therapy for epithelial ovarian cancer (2005) (8)
- Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer (2018) (8)
- A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer. (2011) (8)
- Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer (2017) (8)
- Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC). (2017) (8)
- PTX3 Genetic Variation and Dizygotic Twinning in The Gambia: Could Pleiotropy with Innate Immunity Explain Common Dizygotic Twinning in Africa? (2012) (8)
- Novel MicroRNAs regulating proliferation and apoptosis in uterine papillary serous carcinomas. (2013) (8)
- Hereditary association between testicular cancer and familial ovarian cancer: A Familial Ovarian Cancer Registry study. (2018) (8)
- Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia (2015) (8)
- Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers. (2015) (8)
- Microarray Analysis Reveals Distinct Gene Expression Profiles Among Different Tumor Histology, Stage and Disease Outcomes in Endometrial Adenocarcinoma (2010) (8)
- Structured reporting of T cell assay results. (2013) (8)
- Human ovarian cancer, lymphoma spleen, and bovine milk GlcNAc:β1,4Gal/GalNAc transferases: two molecular species in ovarian tumor and induction of GalNAcβ1,4Glc synthesis by α-lactalbumin (2001) (7)
- Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase. (2010) (7)
- Associations between Gene Expression Variations and Ovarian Cancer Risk Alleles Identified from Genome Wide Association Studies (2012) (7)
- Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass (2021) (7)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy) (2021) (7)
- NY‐ESO‐1 protein glycosylated by yeast induces enhanced immune responses (2010) (7)
- Correction: Frequent MAGE Mutations in Human Melanoma (2010) (7)
- HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. (2016) (7)
- Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer (2021) (7)
- Experience with misoprostol in the management of missed abortion in the second trimester (2005) (7)
- Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation (2021) (7)
- The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report (2016) (7)
- Aldolase mRNA expression in endometrial cancer and the role of clotrimazole in endometrial cancer cell viability and morphology (2011) (7)
- A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors. (2015) (6)
- Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer (2012) (6)
- Submission of the entire lymph node dissection for histologic examination in gynecologic-oncologic specimens. Clinical and pathologic relevance. (2009) (6)
- GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study (2021) (6)
- Contemporary Obstetrics and Gynecology for Developing Countries (2021) (6)
- The use of array‐based comparative genomic hybridization (a‐CGH) to distinguish metastatic from primary synchronous carcinomas of the ovary and the uterus (2008) (6)
- First-inman application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian , breast and prostate cancer patients (2012) (6)
- Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations (2020) (6)
- Recruitment of Intratumoral CD103+ Dendritic Cells by a CXCR4 Antagonist-Armed Virotherapy Enhances Antitumor Immunity (2019) (6)
- Extensive Intratumor Proteogenomic Heterogeneity Revealed by Multiregion Sampling in a High-Grade Serous Ovarian Tumor Specimen (2019) (6)
- Intraobserver and Interobserver Variability in Distinguishing Between Endocervical and Endometrial Adenocarcinoma on Problematic Cases of Cervical Curettings (2008) (5)
- A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891). (2017) (5)
- Transmission of X-linked Ovarian Cancer: Characterization and Implications (2020) (5)
- Methylation of death-associated protein kinase in ovarian carcinomas (2005) (5)
- A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer (2021) (5)
- Evaluation of satisfaction with work–life balance among U.S. Gynecologic Oncology fellows: A cross-sectional study (2016) (5)
- Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use (2016) (5)
- Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women (2019) (5)
- Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR. (2016) (5)
- Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study. (2013) (5)
- Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer (2015) (5)
- Tackling the opioid crisis: Implementation of an ultra-restrictive opioid prescription protocol in patients undergoing major gynecologic surgery radically decreased dispensed opioid without reducing pain control (2018) (5)
- MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma (2021) (4)
- Correction: Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer (2016) (4)
- Correction: Associations between Gene Expression Variations and Ovarian Cancer Risk Alleles Identified from Genome Wide Association Studies (2013) (4)
- Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. (2017) (4)
- rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology (2018) (4)
- Effect of cell-free ascites containing mitochondrial DNA (mtDNA) from ovarian cancer (OC) patients on human neutrophils and neutrophil extracellular traps (NETs). (2014) (4)
- No evidence of association between the genetic predisposition for dizygotic twinning and schizophrenia in West Africa (2004) (4)
- Anthropometric characteristics and ovarian cancer risk and survival (2018) (4)
- Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC) (2022) (4)
- A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types. (2017) (4)
- VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients (2022) (4)
- Towards an animal model of ovarian cancer: cataloging chicken blood proteins using combinatorial peptide ligand libraries coupled with shotgun proteomic analysis for translational research. (2014) (4)
- Satisfaction with work-life balance among U.S. gynecologic oncologists, a cross-sectional study. (2015) (3)
- Phase I trial of the anti-idiotypic monoclonal antibody (mAb) ACA-125 in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer. (2004) (3)
- Immune Checkpoint and Poly(ADP-Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers. (2019) (3)
- Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer. (2002) (3)
- Evidence-based medicine: how do we find the evidence? (1998) (3)
- Identification of dysfunctional CD8+ T-cell subsets rescued by PD-L1 blockade in the tumor microenvironment (2018) (3)
- Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer (2016) (3)
- Phase I/Ib clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac in women with ovarian, Fallopian tube, or peritoneal cancer (OC). (2014) (3)
- RNA Splicing and Immune-Checkpoint Inhibition. (2021) (3)
- A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors (2020) (3)
- Vaccine therapy for cancer: fact or fiction? (2004) (3)
- Cancer in primary immunodeficiency diseases: An analysis of cancer incidence in the United States immune deficiency network (USIDNET) registry. (2016) (3)
- No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival (2016) (3)
- Statins Use Prevents Ovarian Cancer Recurrence in Women with Diabetes Mellitus (2013) (3)
- Expression of NY-ESO-1 cancer testis antigen in prostate cancer. (2017) (2)
- Prospective analysis of chemotherapy-induced neuropathy in patients with gynecologic malignancies. (2011) (2)
- Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer (2022) (2)
- Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer. (2015) (2)
- NY-ESO-1 Vaccination in Combination with Decitabine for Patients with MDS Induces CD4+ and CD8+ T-Cell Responses (2015) (2)
- Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer. (2012) (2)
- History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium (2017) (2)
- Gestational weight gain and risk of epithelial ovarian cancer (2021) (2)
- Co-regulation and functional cooperativity of FOXM1 and RHNO1 bidirectional genes in ovarian cancer (2019) (2)
- Gamma synuclein expression in ovarian cancer (2013) (2)
- Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors. (2016) (2)
- Th 1 / Th 2 CD 4 + T cell responses against NY-ESO-1 in HLA-DPB 1 * 0401 / 0402 patients with epithelial ovarian cancer (2004) (2)
- Tissue residency of memory CD8+ T cells matters in shaping immunogenicity of ovarian cancer. (2022) (2)
- A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY-ESO-1. (2015) (2)
- Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium (2018) (2)
- Immunization of ovarian cancer patients with an NY-ESO-1 peptide of dual MHC class I and II specificities plus incomplete Freund adjuvant induces simultaneous humoral, CD4+ and CD8+ T-cell responses (2005) (2)
- Pyrimidine base damage is increased in women with BRCA mutations. (2013) (2)
- Clinicopathologic outcomes of laser conization for high-grade cervical dysplasia. (2004) (2)
- Higher than expected frequencies of non-ovarian cancers within a large familial ovarian cancer registry. (2015) (2)
- Array-based Comparative Genomic Hybridization (aCGH) Analysis is a Useful Tool for Distinguishing Primary Pulmonary From Metastatic Neuroendocrine Carcinoma to the Lung (2008) (2)
- Necrosis of myometrial choriocarcinoma with fulminating sepsis complicating chemotherapy for trophoblastic tumor. (1998) (2)
- Lessons from a pilot clinical trial of vaccine therapy with an NY-ESO-1 peptide of dual MHC class I and II specificities in ovarian cancer (2005) (2)
- Leadership Diversity and Development in the Nation's Cancer Centers. (2022) (2)
- Synergistic anti-tumor efficacy of combined TLR3 and CD40 neoantigen vaccine requires Batf3-dependent dendritic cells (2018) (2)
- Phase I/II study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results. (2020) (2)
- Chapter 61 – Ovarian Cancer (2013) (2)
- TPTE "Cancer/Testis" antigen is a candidate target for immunotherapy in epithelial ovarian carcinoma (2005) (2)
- Circulating CD14+HLA‐DRlo/− monocytic cells as a biomarker for epithelial ovarian cancer progression (2020) (2)
- Ovarian cancer ascites induces a T cell suppressive phenotype in mature neutrophils: a potential barrier to anti-tumor immunity (2017) (2)
- Proton pump inhibitor use during chemotherapy for platinum-resistant or platinum-refractory ovarian cancer improves overall survival (2018) (2)
- First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients (2012) (2)
- Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study. (2013) (2)
- Adjuvant treatment for uterine leiomyosarcoma. (2012) (2)
- Abstract 956: Novel oral small molecule CXCR4 inhibitor improves activity of immune checkpoint blockade in ovarian cancer mouse model (2017) (1)
- Docetaxel and nab-paclitaxel are safe alternative options for patients with gynecologic malignancies following hypersensitivity reaction to paclitaxel. (2016) (1)
- Evaluation of the impact of chronic steroid use on outcomes in gynecologic cancer patients: A NSQIP database analysis (2016) (1)
- CHAPTER 75 – Molecular Biology of Ovarian Cancer (2009) (1)
- Investigating the impact of asymptomatic leukocytosis on postoperative outcomes in ovarian cancer (2016) (1)
- CASE REPORT Serous Adenocarcinoma of the Uterus Presenting as Paraneoplastic Cerebellar Degeneration (1999) (1)
- Responses for Tumor Immunity T Cell + To Tune Vaccination-Induced CD8 Regulating Mammalian Target of Rapamycin (2012) (1)
- Aspirin and acetaminophen decrease the risk of cervical cancer in long-term users (2014) (1)
- Reprogramming the tumor microenvironment leverages CD8+ T cell responses to a shared tumor/self antigen in ovarian cancer (2023) (1)
- Activation of the COX2-PGE2 axis by immune effector cells results in the self-limiting nature of type-1 immunity in cancer tissues (2014) (1)
- The use of immunotherapy for treatment of chemoresistant ovarian cancer (2021) (1)
- Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (1)
- Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk (2020) (1)
- Instituting a robot‐assisted surgery programme at a tertiary care cancer centre (2010) (1)
- Human ovarian cancer, lymphoma spleen, and bovine milk GlcNAc:beta1,4Gal/GalNAc transferases: two molecular species in ovarian tumor and induction of GalNAcbeta1,4Glc synthesis by alpha-lactalbumin. (2001) (1)
- Methylome Analyses Implicate Fallopian TubeEpithelia as theOrigin forHigh-GradeSerous Ovarian Cancer (2016) (1)
- Gene expression profiling of the endometrium of women with endometriosis using microarray (2003) (1)
- Require STAT 4 T Cell + IL-12-Programmed Long-Term CD 8 (2006) (1)
- Molecular biology of gynecologic cancers (2015) (1)
- Abstract 4557: Tumor immune profiling identifies multiple unique therapeutic targets that improve vaccination + oncolytic virotherapy against metastatic ovarian cancer (2017) (1)
- A human papillomavirus type 16 vaccine. (2003) (1)
- Pelvic exenterations for gynecologic malignancies: 20-year experience at a cancer institute. (2004) (1)
- Vaccination with NY-ESO-1 in Combination with Decitabine for Patients with MDS (2016) (1)
- Abstract IA22: Reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapy (2018) (1)
- Abstract B36: TGFβ blockade and epigenetic modulation for cancer treatment: Efficient breast cancer targeted therapy with TCR-T cell transfer (2020) (1)
- Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial (2023) (1)
- Abstract IA26: Breast tumor microenvironment in black women: A distinct signature of CD8+ T-cell exhaustion (2020) (1)
- Immunogenicity of NY-ESO-1 cancer testis antigen in triple-negative breast cancer. (2012) (1)
- Conventional Dose Hypomethylating Agents Induce CG Antigen Genes In Vivo (2011) (1)
- Abstract LB-18: Statins use prevents ovarian cancer recurrence in women with diabetes mellitus. (2013) (1)
- Surgery induces broad changes in clinically relevant genes regulating immune and metabolic responses in murine epithelial ovarian cancer (2019) (1)
- Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. (2015) (1)
- Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up (2004) (1)
- Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients. (2012) (1)
- Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study (2018) (1)
- TIGIT ligands CD155, CD112, and galectin-9 are associated with immune infiltration and increased overall survival in ovarian cancer (2018) (1)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (1)
- RNA-sequencing reveals immunotherapy targets in gynecological cancer. (2019) (1)
- Evaluating the trend of minimally invasive surgery for cervical cancer: An NSQIP database analysis (2016) (1)
- Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction (2022) (1)
- CXCR6 governs the retention of tissue-resident memory T cells to promote enhanced surveillance and control of ovarian cancer (2020) (1)
- Breaking the silence: Burnout among gynecologic oncology trainees is an impending crisis (2019) (1)
- The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019 (2020) (1)
- Reply to the Letter to the Editor from Schultes et al (2007) (1)
- State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. (2022) (1)
- Pelvic exenterations for gynecologic malignancies: 20-year experience at a cancer institute (2004) (1)
- Exon-specific p53 mutations drive different models of ovarian cancer risk (2015) (1)
- Roleofhumanpapillomavirus indetermining the HLA associated risk ofcervical carcinogenesis (1994) (0)
- Anthropometric characteristics and ovarian cancer risk and survival (2018) (0)
- Targeting the CD47-SIRPα pathway promotes macrophage-mediated trogocytosis of ovarian cancer cells (2021) (0)
- Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation (2023) (0)
- CXCR6 enforced retention promotes resident memory CD8 T cell- mediated immunosurveillance and control of ovarian cancer (2021) (0)
- Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug-resistant, and deadly (2014) (0)
- PAPER 15: Safety and Efficacy of Cytoreductive Surgery for Epithelial Ovarian Cancer in Elderly and Complicated Patients (2005) (0)
- Abstract A53: Combining oncolytic virotherapy with immunotherapy for ovarian cancer treatment. (2016) (0)
- Abstract 5170: Identification of factors secreted by melanoma exhibiting propensity for lung metastases (2011) (0)
- Abstract PR04: Tumor-derived indoleamine 2,3-dioxygenase regulates density of tumor-infiltrating CD8+ T cells and myeloid-derived suppressor cells in a murine model of ovarian cancer (2018) (0)
- 14-3-3 sigma expression and prognostic value in patients with epithelial ovarian carcinoma (2008) (0)
- Abstract PR03: Combinatorial blockade of PD-1, CTLA-4, and LAG-3 pathways inhibits murine ovarian tumor growth. (2016) (0)
- Radiologic Diagnosis of Cancer in Pregnancy (2001) (0)
- Transient mTOR blockade augments vaccination induced CD8 memory responses for tumor immunity (48.21) (2011) (0)
- High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival (2021) (0)
- A comprehensive genomic analysis of neuroendocrine carcinoma of gynecologic and breast tumors (2018) (0)
- Abstract B80: POTE gene expression, epigenetic regulation, and oncogenic functions in human epithelial ovarian cancer (2013) (0)
- Abstract 4844: Polymorphisms in regulatory T cell related genes and ovarian cancer survival. (2013) (0)
- Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies (2013) (0)
- Chronic fatigue and physical distress influence the outcomes of immunotherapy treatment in patients with recurrent ovarian cancer (2021) (0)
- The impact of ovarian cancer spread on survival in advanced epithelial ovarian cancer: A cohort study (2017) (0)
- Distillant - A Glimpse Into the Future of immunotherapy for Gyn Malignancies (2019) (0)
- Immunological changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer. (2017) (0)
- Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer (2018) (0)
- Tumor-derived indoleamine 2,3- dioxygenase regulates density of tumor infiltrating CD8+ T cells and myeloid derived suppressor cells in a murine model of ovarian cancer (2017) (0)
- Rising Burden of Gynaecological Cancers in Developing Countries (2021) (0)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy) (2021) (0)
- Evaluating determinants of prolonged hospitalization following minimally invasive surgery for endometrial cancer (2016) (0)
- Gestational Trophoblastic Disease (2021) (0)
- Adjuvant vaginal brachytherapy alone for high-risk localized endometrial cancer as defined by PORTEC, GOG 99, and Aalders (2008) (0)
- Novel agents to target treatment resistance in ovarian cancer (2021) (0)
- Limited value of routine iron studies prior to initiation of erythropoietin therapy in patients with ovarian cancer (2007) (0)
- Prognostic effects of peripheral and tumor-infiltrating T-cell repertoire diversity in ovarian cancer. (2016) (0)
- Ovarian Cancer Ascites Induces a Suppressor Phenotype in Monocytes that is Abrogated with Complement Inhibition (2020) (0)
- Targeting the VEGF/GD3 immunosuppressive axis in ovarian cancer (2017) (0)
- Cancer Immunity (26 August 2009) Vol. 9, p. 6 (2005) (0)
- Critical Questions in Ovarian Cancer Research and Treatment: Report of an AACR Special Conference (2019) (0)
- Abstract 4753: Ovarian cancer stem cell marker ALDH1A2 is a candidate biomarker for patient selection for intraperitoneal chemotherapy (2016) (0)
- The Prevalence And Clinical Significance Of Mutations BRIP 1 , BARD 1 , PALB 2 And NBN Genes In Women With Ovarian Cancer (2017) (0)
- Galectin-3 Signaling in Donor T Cells Regulates Acute Graft Versus Host Disease (aGvHD) after Allogenic Transplantation (2021) (0)
- Increased physical activity promotes CD8+ lymphocyte infiltration and improves survival in a murine model of ovarian cancer (2020) (0)
- Abstract 606: Targeting multiple immune checkpoints and their ligands using a humanized mouse model of ovarian cancer (2017) (0)
- SU‐GG‐T‐59: Optimization of the Applicator Position in the Treatment of Vaginal Vault HDR Brachytherapy: A Study Based on GEC‐ESTRO Guidelines (2010) (0)
- Epithelial Ovarian Cancer (2021) (0)
- Subcellular localization of AT-rich interactive domain1A protein expression is associated with survival in epithelial ovarian and peritoneal carcinoma (2014) (0)
- The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022 (2023) (0)
- Examination of the time interval between diagnoses in women with metachronous primary endometrial and colorectal cancers supporting universal Lynch testing (2016) (0)
- q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers (2012) (0)
- Cytokine profiling of ascites identifies macrophage inflammatory protein-beta and tumor necrosis factor–alpha as predictors of progression-free survival in patients with epithelial ovarian cancer (2014) (0)
- Synergistic COX2 induction by IFNγ and TNFα self-limits type-1 immunity in cancer tissues (TUM10P.1027) (2015) (0)
- Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a novel approach for adoptive T cell therapy (2015) (0)
- Cancer Vaccines 2005: Closing remarks (2006) (0)
- Transmembrane Phosphatase with TEnsin Homologue (TPTE) Expression in Epithelial Ovarian Cancer (2022) (0)
- Mature neutrophils suppress T cell immunity in the ovarian cancer microenvironment via C3 activation (2018) (0)
- A masterpiece on maternity care in developing countries John B Lawson Kelsey A (2002) (0)
- T Cell Diversity in Tumor May Influence Ovarian Cancer Outcomes (2016) (0)
- 929 The data management and resource sharing center for the cancer moonshot immuno-oncology translational network (2022) (0)
- Cancer relevance of circulating antibodies against LINE-1 antigens in humans (2023) (0)
- Video-based counseling and point-of-contact testing improves genetic screening completion in an ovarian cancer patient population (2020) (0)
- Analytical validation of an immune response assay for classifying solid tumors. (2017) (0)
- Abstract B36: FOXM1 induces DNA replication stress, and its bidirectional gene partner RHNO1 participates in the DNA replication stress response, in high-grade serous ovarian cancer (2018) (0)
- Protein-based vaccination targeting the cancer testis antigen NY-ESO-1 (2008) (0)
- Evaluation of a universal surgical risk calculator for quality improvement on a gynecologic oncology service (2014) (0)
- Indoleamine 2,3-dioxygenase upregulates PD-1 expression on ovarian tumor infiltrating CD8+ T cells via kynurenine activation of the aryl hydrocarbon receptor (2021) (0)
- Decision letter: Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma (2019) (0)
- 000280 OUTCOME OF PATIENTS WITH MUCINOUS OVARIAN CARCINOMA (2005) (0)
- Obesity is an independent predictor of risk for venous thromboembolism in patients undergoing minimally invasive surgery for gynecologic malignancies (2016) (0)
- Oxaliplatin is a safe alternative therapeutic option for patients with recurrent gynecologic cancers following hypersensitivity reaction to carboplatin (2014) (0)
- Molecular Biology of Gynaecological Cancers (2021) (0)
- Mature neutrophils acquire a T cell suppressor phenotype in the ovarian cancer microenvironment that requires complement and NADPH oxidase activation (2019) (0)
- Cancer Immunity (6 February 2006) Vol. 6 Suppl. 1, p. 12 (2005) (0)
- A phase I global trial targeting multiple solid and hematologic malignancies through a NKG2D receptor-based CAR-T immunotherapy (2017) (0)
- Abstract GMM-034: CO-REGULATION AND FUNCTIONAL COOPERATIVITY BETWEEN FOXM1 AND RHNO1 BIDIRECTIONAL GENES IN HIGH-GRADE SEROUS OVARIAN CANCER (2019) (0)
- Natural CXCR3+ FOXP3+ Treg selectively accumulate in human ovarian carcinomas to control type I immunity (127.27) (2012) (0)
- Ex-Th17 Foxp3+ T cells - a novel subset of Foxp3+ T cells induced in cancer (2015) (0)
- Is there a CA-125 level that predicts negative second look surgery (SLS) in patients with advanced epithelail ovarian cancer (EOC)? (2006) (0)
- Metabolomic prediction of endometrial cancer (2017) (0)
- 748 A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumors (2022) (0)
- Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (0)
- Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci (2022) (0)
- Efficacy of a gemcitabine based multiagent chemotherapy regimen for advanced uterine sarcomas. (2006) (0)
- Variability in body mass index (BMI) during adjuvant chemotherapy is associated with clinical outcomes among invasive ovarian cancer patients (2018) (0)
- Venous thromboembolism after minimally invasive surgery for gynecologic malignancy: A NSQIP database analysis (2016) (0)
- Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use. (2016) (0)
- Immune signatures predictive of optimal cytoreduction in ovarian cancer (2012) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Development and stability of Th17 cells in ovarian cancer requires nitric oxide and endogenous NOS2 activity in cancer-associated CD4+ T cells (2013) (0)
- Abstract PR10: Breastfeeding protects against epithelial ovarian cancer: Results of the HOPE Study (2018) (0)
- Ovarian cancer ascites-activated neutrophils suppress T cell proliferation in a contact-dependent mechanism (2016) (0)
- Upregulated Wnt signaling is associated with increased survival of patients with high-grade serous ovarian cancer (2016) (0)
- Abstract LB-87: Association between global DNA hypomethylation in leukocytes and risk of ovarian cancer (2010) (0)
- Abstract 1659: Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer (2012) (0)
- Surgical specialty affects the risk of postoperative complications in ovarian cancer: An analysis of the ACS-NSQIP datasets (2016) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- 6.4 Cancer immunity and clinical oncology (2010) (0)
- Carboplatin enhances lymphocyte-endothelial interactions to promote CD8+ T cell trafficking into the ovarian tumor microenvironment. (2022) (0)
- Abstract A19: Cytoplasmic ARID1A and poor outcome in ovarian cancer patients. (2016) (0)
- Abstract 4442: TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizing agents in monoclonal cells and comparison of clinical outcomes from The Cancer Genome Atlas data (2015) (0)
- carcinogenesis . the HLA associated risk of cervical Role of human papillomavirus in determining (0)
- CM E / SA M IMP 3 Distinguishes Uterine Serous Carcinoma From Endometrial Endometrioid Adenocarcinoma (2010) (0)
- Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature (2016) (0)
- Broad Antigen Specificity T Cell Responses + and CD 4 + Human CD 8 Receptor or DEC-205 In Vitro Elicits Dual Antibody-Targeted NY-ESO-1 to Mannose (2010) (0)
- Abstract 5398: Direct interaction of inhibitory molecules LAG-3 and PD-1 in murine CD8+ T cell signaling (2012) (0)
- BORIS, a novel cancer-testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer (2005) (0)
- 00074 ADJUVANT TREATMENT AND CLINICAL OUTCOME IN STAGE I UTERINE PAPILLARY SEROUS CARCINOMA (2005) (0)
- Expression of the POTE gene family in human ovarian cancer (2018) (0)
- Abstract B12: Genomic and epigenomic characterization of global DNA hypomethylation in human epithelial ovarian cancer (2013) (0)
- Perspectives on Disparities and Equity in Cancer Outcomes: A Call to Action. (2023) (0)
- Peptide Vaccination T Cells following + on Low/High-Avidity CD4 Regulatory T Cells + CD25+ Influence of CD4 (2006) (0)
- Immune biomarkers predictive of survival in epithelial ovarian cancer (2012) (0)
- Serum mitochondrial DNA shows a greater effect size than CA-125 in predicting survival in epithelial ovarian cancer (2015) (0)
- Evaluation of the impact of comprehensive genomic profiling on clinical outcomes in gynecologic oncology patients (2017) (0)
- Evaluation of metachronous breast and endometrial cancers before and after routine adjuvant tamoxifen usage (2016) (0)
- Abstract IA09: Reprogramming T cells for adoptive immunotherapy of ovarian cancer. (2016) (0)
- Phase I study of abagovomab in patients with epithelial ovarian, fallopiantube, or primary peritoneal cancer. Authors' reply (2007) (0)
- Abstract B37: Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer (2020) (0)
- High Distant Failure Rate Despite Good Local Control in High Risk Early Stage Endometrial Cancer (2008) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Performing combined breast and gynecologic surgery does not increase the rate of postoperative morbidity (2018) (0)
- Abstract POSTER-CTRL-1213: Whole exome and targeted resequencing, of population based ovarian cancer cases and controls, identifies susceptibility genes for ovarian cancer (2015) (0)
- Abstract 620: Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient (2017) (0)
- Evaluation of risk factors for readmission following surgery for ovarian cancer: A NSQIP database analysis (2016) (0)
- Can 1H-Nuclear magnetic resonance (NMR) be used for early detection of hepatocellular cancer (HCC)? (2007) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Abstract 947: CXCR4 in combination with immune check point inhibition in ovarian cancer mouse model demonstrates potential for novel therapeutic strategies (2017) (0)
- Targeting family genomic alterations in gynecological malignancies (2019) (0)
- Limited training exposure in intraoperative radiation therapy (IORT) may result in omission of its use in treating locally advanced gynecologic malignancies (2015) (0)
- Real time PCR quantification of COX-2 mRNA in human ovarian epithelial neoplasm and its correlation with clinical outcome (2005) (0)
- Venous thromboembolism in ovarian cancer patients receiving erythropoietin (Epo)/darbepoetin (Darbe) for chemotherapy-induced anemia (CIA) (2008) (0)
- Exploratory analysis of somatic mutations in endometrial cancer and its clinical implications (2019) (0)
- Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer. (2020) (0)
- Preventive strategies and non-invasive treatment options for cervical pre-invasive and invasive disorders (2006) (0)
- Abstract LB-124: Distinct gene expression signatures for endometrial cancer predict for subtype, stage, and prognosis (2010) (0)
- Developing combinatorial approaches for durable cancer treatment (2016) (0)
- Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8+ T‑cells from GzmB mediated self‑destruction (2022) (0)
- Pretreatment serum mitochondrial DNA (mtDNA) correlates with shorter progression-free and overall survival in patients with advanced ovarian cancer (OC). (2014) (0)
- Immune biomarkers associated with response to intra-peritoneal chemotherapy in ovarian cancer (2012) (0)
- Tumor-infiltrating lymphocytes in endometrial cancer with loss of expression in mismatch repair: A cohort study of patients with metachronous colorectal cancer (2016) (0)
- Expression and serum immunoreactivity identify cancer/testis genes 55 and 57 as immunotherapy targets in ovarian cancer (2013) (0)
- Mature neutrophils acquire a T cell suppressor phenotype in the ovarian cancer microenvironment characterized by disruption of key T cell signaling and metabolic responses (2021) (0)
- Abstract LB-186: Sustained efficacy of immunotherapy for solid tumors with novel dual CD4/CD8 T cell receptor engineered synergistic combination of hematopoietic stem cells and T cells (2017) (0)
- Abstract number 2: Duration of intra-chemotherapy anemia is associated with prognosis and survival in epithelial ovarian cancer (2014) (0)
- MDSC-derived and TIL-endogenous NO plays a crucial role in the induction and stability of Th17 cells in human ovarian cancer (TUM4P.915) (2014) (0)
- Role of the extracellular ATP/adenosine pathway in neutrophil-mediated T cell suppression in ovarian cancer microenvironment (2022) (0)
- Tumors by CD 4 Tumor Antigen for Direct Recognition of Peptide-Selective Presentation of Cytosolic Heat Shock Protein 90-Mediated Old and (2012) (0)
- The Race Between Ovarian Cancer and Immunity: How Hormones and Inhibitory Molecules Set the Pace. (2010) (0)
- Association between global DNA hypomethylation in leukocytes and risk of ovarian cancer (2011) (0)
- Abstract 4075: LAG3 and PD1 co-inhibitory molecules directly interact to limit CD8+ T cell signaling (2014) (0)
- The impact of hyperglycemic intensity on postoperative outcomes for a gynecologic oncology service: A cohort study (2016) (0)
- Principles of evidence based screening for cancers. (2000) (0)
- Oral contraceptive use and reproductive characteristics affect survival in patients with epithelial ovarian cancer (2015) (0)
- Correlation of Wilms' tumor 1 (WT1) expression with infiltration by regulatory T cells (Tregs) in epithelial ovarian cancer (2008) (0)
- Immunotherapy for Gynecologic Malignancies (2021) (0)
- Abstract 1623: Minute variation in murine ovarian cancer preclinical models significantly impact immunotherapy results obtained for clinical trial (2017) (0)
- Abstract A05: Expansion of tumor-infiltrating lymphocytes (TIL) using Iovance's Gen 2 process from advanced bladder cancer for adoptive immunotherapy (2020) (0)
- Genomic Assessment of Ovarian Cancer (2010) (0)
- Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use. (2023) (0)
- Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors (2019) (0)
- Intrinsic STING expression inversely associates with survival in ovarian cancer patients (2021) (0)
- Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers (2022) (0)
- γ-synuclein expression in ovarian cancer. (2013) (0)
- Utilization and prognostic impact of somatic tumor testing in ovarian cancer: A single-institution experience (2020) (0)
- Abstract 4754: Overexpression of TSH and ERBB2 (HER2) receptors is associated with sharply decreased survival in high grade serous ovarian cancer (2016) (0)
- Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA (2013) (0)
- Prognostic impact of adjuvant chemotherapy treatment delays for ovarian cancer: A cohort study (2018) (0)
- Abstract 1991: FOXM1 expression in epithelial ovarian cancer coincides with gene amplification and functional loss of p53 and Rb and drives G2-M progression and target gene expression (2015) (0)
- How much is too much? Ending excessive opioid prescribing after major gynecologic oncology procedures (2019) (0)
- Adoptive Cell Therapy for Nonhematologic Solid Tumors. (2023) (0)
- Frequencies of nonovarian cancers within the Gilda Radner Familial Ovarian Cancer Registry (2013) (0)
- Abstract 803: Expression of poly(adenosine diphosphate-ribose) polymerase (PARP) and p53 in epithelial ovarian cancer (2010) (0)
- Operative time is a major modifiable risk factor impacting surgical outcomes in patients undergoing pelvic exenteration for gynecologic malignancy (2018) (0)
- Impact of residents and fellows on postoperative outcomes in gynecologic cancer patients: An analysis of the ACS-NSQIP database (2016) (0)
- High-grade serous ovarian cancer primary tumor BRCA1 mRNA expression is a candidate biomarker for patient selection for intraperitoneal chemotherapy (2016) (0)
- Evaluation of smoking as a risk factor for adverse postoperative outcomes in endometrial cancer: A study of the NSQIP database (2016) (0)
- Preliminary validation of nCounter PanCancer immune profiling of FFPE slides and pbmc in CITN-05, a CITN study of the immunological effects of an IDO1 inhibitor in patients with ovarian carcinoma (2015) (0)
- Abstract MIP-044: FOXM1 INDUCED REPLICATION STRESS IS MITIGATED BY ITS BIDIRECTIONAL GENE PARTNER, RHNO1, IN HIGH GRADE SEROUS OVARIAN CANCER (2017) (0)
- Principles of Evidence Based Screening for Cancers. (2000) (0)
- NY-ESO-1 is associated with an aggressive phenotype of ovarian cancer (2017) (0)
- Targeting myeloid cells in the tumor microenvironment as a strategy to enhance vaccine efficacy in epithelial ovarian cancer (2014) (0)
- Human leukocyte antigen polymorphisms predict NY-ESO-1 tumor antigen serology and overall survival in epithelial ovarian cancer (2013) (0)
- A phase II, pharmacokinetic (PK), and pharmacodynamic (PD) study of weekly docetaxel (DOC) in patients with platinum-resistant ovarian cancer. (2016) (0)
- Tumor-infiltrating T lymphocyte clonality predicts prognosis in human ovarian cancer (2013) (0)
- Impact of ascites volume on clinical outcomes in epithelial ovarian cancer: A cohort study (2017) (0)
- Identification of a subset of stage IV ovarian carinomas with improved overall survival (2012) (0)
- Intratumoral B cells as predictive biomarkers for response to immune check point blockade in patients with recurrent ovarian cancer (2021) (0)
- Immunologic markers of cancer progression and prognosis. (2007) (0)
- Abstract B55: Recurrent transcriptional remodeling events and acquired fusion RNAs in relapsed ovarian cancers (2018) (0)
- Developmentally restricted differentiation antigens in human ovarian cancer (2008) (0)
- real time observation of tumor-host interaction during ovarian cancer cytoreductive surgery using intravital microsocopy (2019) (0)
- Abstract 1983: Cancer exosomes immunosuppressive activity in the absence of contaminating soluble factors is multifactorial (2019) (0)
- Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC) (2019) (0)
- Unfitness and cancer: State-of-the-art activity tracking devices reveal the unexpectedly sedentary lives of our cancer patients (2019) (0)
- Abstract A35: Ovarian cancer stem cells subvert tumor-specific T cells by disrupting T cells’ metabolic fitness (2018) (0)
- Abstract 414: Prospective profiling of systemic and loco-regional alterations during intraperitoneal chemotherapy for ovarian cancer, results from GOG 271 (2015) (0)
- Author response: Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer (2021) (0)
This paper list is powered by the following services:
Other Resources About Kunle Odunsi
What Schools Are Affiliated With Kunle Odunsi?
Kunle Odunsi is affiliated with the following schools:
